The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Collaboration integrates SmartChip PCR technology with cloud-based analytics to enable faster, standardised monitoring of antimicrobial resistance
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Subscribe To Our Newsletter & Stay Updated
